Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle-Reference-Cited by-同舟云学术

Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle

Published:2017-07-13 Issue:14 Volume:60 Page:6364-6383
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

He Shanshan¹,Li Kelin²,Lin Billy¹,Hu Zongyi¹,Xiao Jingbo³,Hu Xin³,Wang Amy Q.³,Xu Xin³,Ferrer Marc³,Southall Noel³,Zheng Wei³,Aubé Jeffrey²^ORCID,Schoenen Frank J.²,Marugan Juan J.³,Liang T. Jake¹,Frankowski Kevin J.²^ORCID

Affiliation:

1. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892-1800, United States

2. University of Kansas Specialized Chemistry Center, University of Kansas, Lawrence, Kansas 66047, United States

3. Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States

Funder

U.S. Department of Health and Human Services

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00561

Reference23 articles.

1. Epidemiology of Hepatitis B and C Viruses: A Global Overview

2. Treatment of hepatitis C in difficult-to-treat patients

3. Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C